Role of 4-1BB (CD137) in the functional activation of cord blood CD28-CD8+ T cells

被引:34
作者
Kim, YJ
Brutkiewicz, RR
Broxmeyer, HE
机构
[1] Indiana Univ, Sch Med, Walther Oncol Ctr, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA
[2] Walther Canc Inst, Indianapolis, IN USA
关键词
D O I
10.1182/blood-2001-11-0136
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The CD28(-) subset of CD8(+) T cells is associated with cytotoxic T lymphocyte (CTL) effector function. We investigated a potential role for 4-1BB, a costimulatory molecule structurally related to members of the tumor necrosis factor (TNF) receptor family, in the generation and functional activation of CD28(-) CTLs by using human cord blood (CB) cells composed exclusively of naive CD8+ T cells with few or no CD28(-) CTLs. The 4-1BB was induced preferentially on the CB CD28(-)CD8(+) T cells when CD28 down-regulation was induced by interleukin 15 (IL-15) and IL-12 stimulation. Anti-4-1BB costimulation induced dramatic phenotypic changes in the CD28- CTLs, including restoration of CD28 expression as well as that of memory markers such as CD45RO and CC chemokine receptor 6 (CCR6). Anti-4-1BB costimulation also promoted long-term survival of CD28(-) CTLs, which were sensitive to activation-induced cell death upon anti-CD3 stimulation. The memory-type CD28(+) CTLs induced by anti-4-1BB costimulation acquired a greatly enhanced content of granzyme B, a cytolytic mediator, and enhanced cytotoxic activity as compared with CD28(-) CTLs. Strong cytotoxicity of memory-type CTLs to a 4-1BB ligand-expressing Epstein-Barr virus (EBV)-transformed B-cell line was almost completely abrogated by 4-1BB-Fc, a soluble form of 4-1BB, suggesting involvement of 4-1BB in cytolytic processes. Taken all together, our results suggest that 4-1BB plays a role in the differentiation of effector memory CTLs. (C) 2002 by The American Society of Hematology.
引用
收藏
页码:3253 / 3260
页数:8
相关论文
共 65 条
[1]   HIV-specific CD8+ T cells produce antiviral cytokines but are impaired in cytolytic function [J].
Appay, V ;
Nixon, DF ;
Donahoe, SM ;
Gillespie, GMA ;
Dong, T ;
King, A ;
Ogg, GS ;
Spiegel, HML ;
Conlon, C ;
Spina, CA ;
Havlir, DV ;
Richman, DD ;
Waters, A ;
Easterbrook, P ;
McMichael, AJ ;
Rowland-Jones, SL .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (01) :63-75
[2]  
AZUMA M, 1993, J IMMUNOL, V150, P1147
[3]   Cytolytic mechanisms and expression of activation-regulating receptors on effector-type CD8+CD45RA+CD27- human T cells [J].
Baars, PA ;
do Couto, LMR ;
Leusen, JHW ;
Hooibrink, B ;
Kuijpers, TW ;
Lens, SMA ;
van Lier, RAW .
JOURNAL OF IMMUNOLOGY, 2000, 165 (04) :1910-1917
[4]   Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients [J].
Blazar, BR ;
Kwon, BS ;
Panoskaltsis-Mortari, A ;
Kwak, KB ;
Peschon, JJ ;
Taylor, PA .
JOURNAL OF IMMUNOLOGY, 2001, 166 (05) :3174-3183
[5]   Loss of CD28 expression on CD8+ T cells is induced by IL-2 receptor γ chain signalling cytokines and type IIFN, and increases susceptibility to activation-induced apoptosis [J].
Borthwick, NJ ;
Lowdell, M ;
Salmon, M ;
Akbar, AN .
INTERNATIONAL IMMUNOLOGY, 2000, 12 (07) :1005-1013
[6]   LYMPHOCYTE-ACTIVATION IN HIV-1 INFECTION .2. FUNCTIONAL DEFECTS OF CD28- T-CELLS [J].
BORTHWICK, NJ ;
BOFILL, M ;
GOMBERT, WM ;
AKBAR, AN ;
MEDINA, E ;
SAGAWA, K ;
LIPMAN, MC ;
JOHNSON, MA ;
JANOSSY, G .
AIDS, 1994, 8 (04) :431-441
[7]  
BROXMEYER HE, 1999, HEMATOPOIETIC CELL T, P441
[8]   CD8+ T-cell selection, function, and death in the primary immune response in vivo [J].
Callan, MFC ;
Fazou, C ;
Yang, HB ;
Rostron, T ;
Poon, K ;
Hatton, C ;
McMichael, AJ .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 106 (10) :1251-1261
[9]   4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy [J].
Cannons, JL ;
Lau, P ;
Ghumman, B ;
DeBenedette, MA ;
Yagita, H ;
Okumura, K ;
Watts, TH .
JOURNAL OF IMMUNOLOGY, 2001, 167 (03) :1313-1324
[10]   Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation [J].
Chen, SH ;
Pham-Nguyen, KB ;
Martinet, O ;
Huang, YZ ;
Yang, W ;
Thung, SN ;
Chen, LP ;
Mittler, R ;
Woo, SLC .
MOLECULAR THERAPY, 2000, 2 (01) :39-46